Boswellia for Inflammatory Bowel Disease

Inflammatory bowel disease is one of the most mechanistically logical — and one of the most honestly disappointing — uses of Boswellia. The rationale is genuinely strong: leukotriene B4 is elevated in the inflamed mucosa of the gut, and Boswellia's boswellic acids inhibit the enzyme that makes it. Several small, mostly older trials in ulcerative colitis and chronic colitis were positive, and a collagenous-colitis trial reached remission. But the single largest, most rigorous study — a 108-patient, placebo-controlled trial of Boswellia for maintaining remission in Crohn's disease — found no benefit over placebo, even though the extract was safe. This page presents the whole picture, including the trials that did not work, so that expectations are grounded in the actual science rather than in the promise of the mechanism.

Table of Contents

  1. Why the Gut Is a Logical Target: Leukotriene B4
  2. Ulcerative Colitis: The Early Gupta Trials
  3. Chronic Colitis
  4. Crohn's Disease: The H15 Non-Inferiority Trial
  5. The Negative Crohn's Maintenance Trial
  6. Collagenous (Microscopic) Colitis
  7. How to Interpret This Mixed Evidence
  8. Practical Considerations for Patients
  9. Cautions
  10. Key Research Papers
  11. External Resources
  12. Connections
  13. Featured Videos

Why the Gut Is a Logical Target: Leukotriene B4

The intestinal mucosa in active inflammatory bowel disease is flooded with inflammatory mediators, and one of the most prominent is leukotriene B4 (LTB4). LTB4 is a powerful chemoattractant — it recruits neutrophils into the gut wall, where they release enzymes and reactive oxygen species that damage the epithelium and perpetuate ulceration. Concentrations of LTB4 in inflamed colonic tissue can be markedly elevated compared with healthy mucosa.

LTB4 is produced by the 5-lipoxygenase pathway — precisely the enzyme that Boswellia's AKBA inhibits, as detailed on the mechanism page. On paper, then, a 5-lipoxygenase inhibitor is an almost tailor-made intervention for IBD: reduce LTB4, reduce neutrophil recruitment, reduce mucosal damage. This is the same logic that drove pharmaceutical interest in leukotriene-pathway drugs for IBD decades ago.

The lesson that emerges from the actual trials, however, is a familiar one in medicine: a compelling mechanism does not guarantee a clinical effect. The body is more complicated than a single pathway, drug delivery to the inflamed tissue matters, and IBD is driven by many overlapping inflammatory circuits. Boswellia's IBD story is a case study in why we run randomized trials rather than reasoning from mechanism alone.

Back to Table of Contents

Ulcerative Colitis: The Early Gupta Trials

The earliest human evidence came from a group led by Gupta. In a 1997 study published in the European Journal of Medical Research, patients with ulcerative colitis were treated with a Boswellia serrata gum resin preparation (350 mg three times daily) for six weeks. The reported results were striking: a high proportion of patients treated with Boswellia went into remission, with improvements in stool properties, rectal biopsy findings, and blood parameters that the authors described as comparable to the sulfasalazine comparison group.

On its face this is an impressive result. But several cautions are essential. The trial was small, it was conducted at a single center, and its methodology and reporting fall short of modern standards for IBD trials — there was no placebo arm in the usual double-blind sense, and remission was defined and measured differently than in contemporary studies. A high remission percentage in a small, older, open comparison should be treated as a hypothesis-generating signal, not as proof that Boswellia rivals standard therapy.

Back to Table of Contents

Chronic Colitis

The same research group followed up with a study in patients with chronic colitis, published in Planta Medica in 2001. Again using a Boswellia serrata gum resin preparation, the authors reported that a majority of treated patients achieved remission, with the herb again compared favorably against a sulfasalazine reference group.

These two Gupta studies are the backbone of the popular claim that Boswellia treats ulcerative colitis, and they are genuinely encouraging as early-stage evidence. Yet they share the same limitations — small numbers, single-group settings, older methodology, and a research team with a consistent interest in the herb. What the field needed was larger, independent, rigorously blinded replication. That replication, when it came in the related setting of Crohn's disease, delivered a more sobering result.

Back to Table of Contents

Crohn's Disease: The H15 Non-Inferiority Trial

The first substantial Crohn's trial was published by Gerhardt and colleagues in Zeitschrift für Gastroenterologie in 2001. It compared a Boswellia serrata extract known as H15 against mesalazine (a standard 5-aminosalicylate IBD drug) in patients with active Crohn's disease, using the Crohn's Disease Activity Index (CDAI) as the primary outcome.

The finding was that H15 was not inferior to mesalazine in reducing the CDAI — the two treatments produced broadly similar improvements. The authors interpreted this non-inferiority as evidence of efficacy for Boswellia in active Crohn's disease.

It is important to read a non-inferiority result carefully. Showing that a herb is “not worse than” a comparator is only as persuasive as the comparator's own proven effect in that trial — and mesalazine's efficacy in Crohn's disease is itself modest and debated. Without a placebo arm, a non-inferiority result can also arise if neither treatment did much. So while this trial is often cited as positive, it is weaker evidence than a placebo-controlled superiority trial would be.

Back to Table of Contents

The Negative Crohn's Maintenance Trial

The most rigorous test of Boswellia in IBD to date was the trial by Holtmeier and colleagues, published in Inflammatory Bowel Diseases in 2011. This was a proper randomized, placebo-controlled, double-blind study conducted across 22 German centers, enrolling 108 outpatients with Crohn's disease who were in clinical remission. Patients received either a Boswellia serrata extract (Boswelan) or placebo for up to 52 weeks, with the goal of maintaining that remission.

The result was clearly negative. Roughly 60% of the Boswellia group and 55% of the placebo group stayed in remission — a difference that was not statistically significant. The time to relapse was also essentially the same in both groups. The one genuinely positive finding was safety: the extract was well tolerated over a full year of use, confirming Boswellia's benign side-effect profile even in long-term treatment.

This trial matters more than any of the earlier positive studies for one simple reason: it was the largest and best-designed. When a properly powered, multicenter, placebo-controlled trial fails to beat placebo, that outcome deserves substantial weight — more than several small, older, non-placebo-controlled studies pointing the other way. The honest conclusion is that Boswellia has not been shown to maintain remission in Crohn's disease, and it should not be relied upon for that purpose.

Back to Table of Contents

Collagenous (Microscopic) Colitis

A distinct and often-overlooked strand of evidence involves collagenous colitis, a form of microscopic colitis that causes chronic watery diarrhea. Madisch and colleagues published a double-blind, randomized, placebo-controlled, multicenter trial in the International Journal of Colorectal Disease in 2007, testing Boswellia serrata extract (3 × 400 mg daily) over six weeks.

In this trial, a substantially higher proportion of patients on Boswellia achieved clinical remission compared with placebo. This is a placebo-controlled positive signal in a specific, well-defined condition, which makes it more interesting than the older open comparisons. The trial was still small, however, and analyses that account for dropouts weaken the certainty, so it is best described as a promising but not definitive result that warrants larger confirmation.

Back to Table of Contents

How to Interpret This Mixed Evidence

Putting the whole IBD literature together, a fair reader should reach a nuanced conclusion rather than a slogan:

The most defensible summary is that Boswellia is investigational for IBD: mechanistically promising, occasionally positive in small studies, but not proven in the strongest trial and therefore not a substitute for established therapy. It may hold more promise as a well-tolerated adjunct in milder or specific presentations than as a stand-alone treatment for moderate-to-severe disease.

Back to Table of Contents

Practical Considerations for Patients

For someone living with IBD who is curious about Boswellia, a few grounded points apply:

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Gupta I, Parihar A, Malhotra P, et al. (1997). Effects of Boswellia serrata gum resin in patients with ulcerative colitis. European Journal of Medical Research. — PubMed 9049593
  2. Gupta I, Parihar A, Malhotra P, et al. (2001). Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Medica. — PubMed 11488449
  3. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R (2001). Therapy of active Crohn disease with Boswellia serrata extract H 15. Zeitschrift für Gastroenterologie. — PubMed 11215357
  4. Holtmeier W, Zeuzem S, Preiss J, et al. (2011). Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflammatory Bowel Diseases. — PubMed 20848527
  5. Madisch A, Miehlke S, Eichele O, et al. (2007). Boswellia serrata extract for the treatment of collagenous colitis: a double-blind, randomized, placebo-controlled, multicenter trial. International Journal of Colorectal Disease. — PubMed 17764013
  6. Safayhi H, Mack T, Sabieraj J, et al. (1992). Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. Journal of Pharmacology and Experimental Therapeutics. — PubMed 1602379
  7. Ammon HP (2006). Boswellic acids in chronic inflammatory diseases. Planta Medica. — PubMed 17024588
  8. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M (2011). Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clinical Pharmacokinetics. — PubMed 21553931

PubMed Topic Searches

  1. PubMed: Boswellia serrata ulcerative colitis
  2. PubMed: Boswellia serrata Crohn's disease
  3. PubMed: Leukotriene B4 in IBD mucosa
  4. PubMed: Boswellia collagenous/microscopic colitis
  5. PubMed: 5-LOX inhibitors in IBD

Back to Table of Contents

External Resources

Back to Table of Contents

Connections

Back to Table of Contents